These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 13129490)

  • 1. First-line treatment regimens and the role of consolidation therapy in advanced ovarian cancer.
    Stuart GC
    Gynecol Oncol; 2003 Sep; 90(3 Pt 2):S8-15. PubMed ID: 13129490
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Medical therapy of advanced malignant epithelial tumours of the ovary.
    Colombo N; Parma G; Bocciolone L; Franchi D; Sideri M; Maggioni A
    Forum (Genova); 2000; 10(4):323-32. PubMed ID: 11535983
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epithelial ovarian cancer.
    Hensley ML
    Curr Treat Options Oncol; 2002 Apr; 3(2):131-41. PubMed ID: 12057076
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Emerging role of topotecan in front-line treatment of carcinoma of the ovary.
    Coleman RL
    Oncologist; 2002; 7 Suppl 5():46-55. PubMed ID: 12324633
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New options for the treatment of advanced ovarian cancer.
    Dunton CJ
    Semin Oncol; 1997 Feb; 24(1 Suppl 5):S5-2-S5-11. PubMed ID: 9122739
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Low drug resistance to both platinum and taxane chemotherapy on an in vitro drug resistance assay predicts improved survival in patients with advanced epithelial ovarian, fallopian and peritoneal cancer.
    Matsuo K; Bond VK; Eno ML; Im DD; Rosenshein NB
    Int J Cancer; 2009 Dec; 125(11):2721-7. PubMed ID: 19530239
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sequential topotecan and oral etoposide in recurrent ovarian carcinoma pretreated with platinum-taxane. Results from a multicenter phase I/II study.
    Gronlund B; Engelholm SA; Horvath G; Mäenpää J; Ridderheim M
    Cancer; 2005 Apr; 103(7):1388-96. PubMed ID: 15719439
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Anthracyclines in therapy of ovarian carcinoma: a systematic review of primary and 2nd-line therapy after platinum].
    du Bois A; Lück HJ; Pfisterer J; Meier W; Bauknecht T
    Zentralbl Gynakol; 2000; 122(5):255-67. PubMed ID: 10857212
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Survival benefits with diverse chemotherapy regimens for ovarian cancer: meta-analysis of multiple treatments.
    Kyrgiou M; Salanti G; Pavlidis N; Paraskevaidis E; Ioannidis JP
    J Natl Cancer Inst; 2006 Nov; 98(22):1655-63. PubMed ID: 17105988
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Usefulness of third-line chemotherapy for women with recurrent ovarian, fallopian tube, and primary peritoneal cancer who receive platinum/taxane regimens as first-line therapy.
    Nishio S; Katsumata N; Matsumoto K; Tanabe H; Yonemori K; Kouno T; Shimizu C; Ando M; Kamura T; Kasamatsu T; Fujiwara Y
    J Cancer Res Clin Oncol; 2009 Apr; 135(4):551-7. PubMed ID: 18830625
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase 2 trial of prolonged administration of oral topotecan in platinum/taxane-refractory ovarian, fallopian tube, and primary peritoneal cancers.
    Markman M; Webster K; Zanotti K; Kulp B; Peterson G; Belinson J
    Gynecol Oncol; 2004 Oct; 95(1):109-13. PubMed ID: 15385118
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Topotecan versus treosulfan, an alkylating agent, in patients with epithelial ovarian cancer and relapse within 12 months following 1st-line platinum/paclitaxel chemotherapy. A prospectively randomized phase III trial by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group (AGO-OVAR).
    Meier W; du Bois A; Reuss A; Kuhn W; Olbricht S; Gropp M; Richter B; Lück HJ; Kimmig R; Pfisterer J
    Gynecol Oncol; 2009 Aug; 114(2):199-205. PubMed ID: 19446314
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Topotecan: prospects for using it in combination therapy for ovarian carcinoma].
    Scarfone G
    Tumori; 1999; 85(6 Suppl 1):S12-5. PubMed ID: 10786195
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Optimal sequencing in the treatment of recurrent ovarian cancer.
    Spriggs D
    Gynecol Oncol; 2003 Sep; 90(3 Pt 2):S39-44. PubMed ID: 13129495
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Current therapies in ovarian cancer.
    Fields AL; Runowicz CD
    Cancer Invest; 2003; 21(1):148-56. PubMed ID: 12643016
    [No Abstract]   [Full Text] [Related]  

  • 16. The effect of hospital operative volume, residual tumor and first-line chemotherapy on survival of ovarian cancer - a prospective nation-wide study in Finland.
    Kumpulainen S; Sankila R; Leminen A; Kuoppala T; Komulainen M; Puistola U; Hurme S; Hiekkanen H; Mäkinen J; Grénman S
    Gynecol Oncol; 2009 Nov; 115(2):199-203. PubMed ID: 19695688
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gefitinib in combination with tamoxifen in patients with ovarian cancer refractory or resistant to platinum-taxane based therapy--a phase II trial of the AGO Ovarian Cancer Study Group (AGO-OVAR 2.6).
    Wagner U; du Bois A; Pfisterer J; Huober J; Loibl S; Lück HJ; Sehouli J; Gropp M; Stähle A; Schmalfeldt B; Meier W; Jackisch C;
    Gynecol Oncol; 2007 Apr; 105(1):132-7. PubMed ID: 17161453
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New and emerging intraperitoneal (IP) drugs for ovarian cancer treatment.
    Muggia FM
    Semin Oncol; 2006 Dec; 33(6 Suppl 12):S18-24. PubMed ID: 17223446
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A cost-effectiveness analysis of chemotherapy for patients with recurrent platinum-sensitive epithelial ovarian cancer.
    Case AS; Rocconi RP; Partridge EE; Straughn JM
    Gynecol Oncol; 2007 Apr; 105(1):223-7. PubMed ID: 17215031
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of maximal surgical cytoreduction on sensitivity to platinum-taxane chemotherapy and subsequent survival in patients with advanced ovarian cancer.
    Eisenhauer EL; Abu-Rustum NR; Sonoda Y; Aghajanian C; Barakat RR; Chi DS
    Gynecol Oncol; 2008 Feb; 108(2):276-81. PubMed ID: 18063020
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.